Piper Sandler starts coverage on Pelthos Therapeutics with Overweight rating and $48 price target, highlighting ZELSUVMI as a promising new treatment for common viral skin infection molluscum contagiosum with peak U.S. sales potentially over $200M.
TD Cowen notes Roche's $150 per genome consumables price for its new Axelios nanopore sequencer came in higher than expected, offering short-term relief to Illumina's market position.
X4 Pharmaceuticals receives positive CHMP opinion for mavorixafor, the potential first EU therapy for ultra-rare WHIM syndrome. EC decision expected Q2 2026.
Neurogene’s NGN-401 gene therapy just received FDA Breakthrough Therapy Designation for Rett syndrome. Early trial results show lasting improvements in skills and daily life.
CMS resolves hypoglossal nerve stimulation reimbursement confusion by adding 6 new HCPCS codes (effective Jan 1, 2026), viewed as positive for Inspire & Nyxoah.
uniQure shares fell about 33% after FDA Commissioner Marty Makary's comments on rare disease drugs. But analysts say his remarks likely targeted another therapy, not uniQure's AMT-130 for Huntington's disease.
